Hypoglycemic and antilipidemic properties of kombucha tea in alloxan-induced diabetic rats

Laboratory of Biochemistry and Enzymatic Engineering of Lipases, National School of Engineers of Sfax, University of Sfax, Tunisia.
BMC Complementary and Alternative Medicine (Impact Factor: 2.02). 05/2012; 12(1):63. DOI: 10.1186/1472-6882-12-63
Source: PubMed

ABSTRACT Diabetes has become a serious health problem and a major risk factor associated with troublesome health complications, such as metabolism disorders and liver-kidney dysfunctions. The inadequacies associated with conventional medicines have led to a determined search for alternative natural therapeutic agents. The present study aimed to investigate and compare the hypoglycemic and antilipidemic effects of kombucha and black tea, two natural drinks commonly consumed around the world, in surviving diabetic rats.
Alloxan diabetic rats were orally supplied with kombucha and black tea at a dose of 5 mL/kg body weight per day for 30 days, fasted overnight, and sacrificed on the 31st day of the experiment. Their bloods were collected and submitted to various biochemical measurements, including blood glucose, cholesterol, triglcerides, urea, creatinine, transaminases, transpeptidase, lipase, and amylase activities. Their pancreases were isolated and processed to measure lipase and α-amylase activities and to perform histological analysis.
The findings revealed that, compared to black tea, kombucha tea was a better inhibitor of α-amylase and lipase activities in the plasma and pancreas and a better suppressor of increased blood glucose levels. Interestingly, kombucha was noted to induce a marked delay in the absorption of LDL-cholesterol and triglycerides and a significant increase in HDL-cholesterol. Histological analyses also showed that it exerted an ameliorative action on the pancreases and efficiently protected the liver-kidney functions of diabetic rats, evidenced by significant decreases in aspartate transaminase, alanine transaminase, and gamma-glytamyl transpeptidase activities in the plasma, as well as in the creatinine and urea contents.
The findings revealed that kombucha tea administration induced attractive curative effects on diabetic rats, particularly in terms of liver-kidney functions. Kombucha tea can, therefore, be considered as a potential strong candidate for future application as a functional supplement for the treatment and prevention of diabetes.

Download full-text


Available from: Khaled Hamden, Feb 13, 2014
150 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes is a serious health problem and a source of risk for numerous severe complications such as obesity and hypertension. Treatment of diabetes and its related diseases can be achieved by inhibiting key digestive enzymes related to starch and lipid digestion. The findings revealed that the administration of trigonelline to surviving diabetic rats helped to protect the pancreas β-cells from death and damage. Additionally, the supplement of trigonelline to surviving diabetic rats significantly decreased intestinal α-amylase and maltase by 36 and 52%, respectively, which led to a significant decrease in the blood glucose rate by 46%. Moreover, the administration of trigonelline to surviving diabetic rats potentially inhibited key enzymes of lipid metabolism and absorption such as lipase activity in the small intestine by 56%, which led to a notable decrease in serum triglyceride (TG) and total cholesterol (TC) rates and an increase in the HDL cholesterol level. This treatment also improved glucose, maltase, starch, and lipid oral tolerance. Trigonelline was also observed to protect the liver-kidney functions efficiently, which was evidenced by the significant decrease in the serum aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (GGT), and lactate dehydrogenase (LDH) activities and creatinine, albumin, and urea rates. The histological analysis of the pancreas, liver, and kidney tissues further established the positive effect of trigonelline. Overall, the findings presented in this study demonstrate that the administration of trigonelline to diabetic rats can make it a potentially strong candidate for industrial application as a pharmacological agent for the treatment of hyperglycemia, hyperlipidemia, and liver-kidney dysfunctions.
    Scientia Pharmaceutica 03/2013; 81(1):233-46. DOI:10.3797/scipharm.1211-14
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the antioxidant and radical scavenging activities of saponins from Solanum anguivi fruit (SAGU) and its possible effect on oxidative status of rat exposed to alloxan-induced diabetes. Methods: Antioxidant activity of SAGU was assayed by using 2,2'-azino-bis3-ethylbenzothiazoline-6-sulphonic acid (ABTS), reducing power, iron chelation and ability to inhibit lipid peroxidation in both liver and brain homogenates of rats. Also, the effect of SAGU on MDA level, an indicator of lipid peroxidation and activity of superoxide dismutase (SOD) and catalase (CAT) were determined in heart and kidney of rat exposed to alloxan (150mg/kg) for 21 days. Results: SAGU exhibited potent and concentration dependent free radical-scavenging activity (IC50/ABTS = 290.12 ± 1.34µg/ml). Reductive and iron chelation abilities also increase with increase in SAGU concentration. SAGU also inhibited peroxidation of hepatic and cerebral lipids subjected to iron oxidative assault. In addition, SAGU significantly (P<0.05) protected against lipid peroxidation induced by alloxan as well as restored the level of SOD and CAT in both heart and kidney of alloxan-treated rats. Conclusions: Taking together, our results suggest that saponins from the fruits of Solanum anguivi are potent antioxidant that can be useful not only in pharmaceutical and food industry, but also in the management of diabetes.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract The present study investigated the effect of treating diabetic rats with eugenol (EG). In vitro enzyme activity was measured in the presence of eugenol, and it was found to inhibit pancreatic α-amylase (IC50 = 62.53 µg/mL) and lipase (IC50 = 72.34 µg/mL) as well as angiotensin converting enzyme (ACE) activity (IC50 = 130.67 µg/mL). In vivo, EG reduced the activity of amylase in serum, pancreas and intestine also the peak level of glucose by 60% compared to diabetic rats. Furthermore, eugenol similar to acarbose reduced serum glycosylated hemoglobin (HbA1c), lipase and ACE levels. In addition, treatments with EG showed notable decrease in serum total-cholesterol, triglycerides and low density lipoprotein-cholesterol levels with an increase of high density lipoprotein-cholesterol. Overall, EG significantly reverted back to near normal the values of the biochemical biomarkers such as transaminases (AST&ALT), alkaline phosphatase (ALP), creatine phosphokinase (CPK) and gamma-glutamyl transpeptidase (GGT) activities, total-bilirubin, creatinine, urea and uric acid rates.
    Archives of Physiology and Biochemistry 07/2013; 119(5). DOI:10.3109/13813455.2013.822521 · 1.76 Impact Factor
Show more